| Diabetes Mellitus, Non-Insulin-Dependent
Jardiance vs Soliqua
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Jardiance vs Soliqua 100/33 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliqua 100/33 has a higher rate of injection site reactions vs Jardiance based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliqua 100/33 but not Jardiance, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jardiance
Soliqua 100/33
At A Glance
Oral
Once daily
SGLT2 inhibitor
SC injection
Once daily
Basal insulin + GLP-1 receptor agonist
Indications
- Heart failure
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Heart failure, Chronic Kidney Diseases 10 mg orally once daily in the morning, taken with or without food.
Diabetes Mellitus, Non-Insulin-Dependent 10 mg orally once daily in the morning, taken with or without food; may increase to 25 mg once daily in patients tolerating 10 mg for additional glycemic control.
Diabetes Mellitus, Non-Insulin-Dependent 15 units SC once daily for patients naive to basal insulin or GLP-1 receptor agonist, on a GLP-1 receptor agonist, or on <30 units basal insulin daily; 30 units SC once daily for patients on 30-60 units basal insulin daily; titrate by 2-4 units weekly; max 60 units (60 units insulin glargine/20 mcg lixisenatide) daily; inject within 1 hour prior to first meal of the day.
Contraindications
- Hypersensitivity to empagliflozin or any excipient in JARDIANCE (reactions such as angioedema have occurred)
- Hypoglycemia episodes
- Serious hypersensitivity to insulin glargine, lixisenatide, or any excipient in SOLIQUA 100/33
Adverse Reactions
Most common (>=2%) Urinary tract infection, female genital mycotic infections, upper respiratory tract infection, increased urination, dyslipidemia, arthralgia, male genital mycotic infections, nausea
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypoglycemia (with insulin or sulfonylurea), hypersensitivity reactions
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, skin reactions (rash, urticaria)
Most common (>=5%) Nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache, hypoglycemia
Serious Anaphylaxis, serious hypersensitivity, acute pancreatitis, hypoglycemia, acute kidney injury due to volume depletion, hypokalemia, acute gallbladder disease, pulmonary aspiration during general anesthesia or deep sedation
Postmarketing Localized cutaneous amyloidosis (insulin glargine); acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation, cholecystitis, cholelithiasis, dysgeusia, dysesthesia, pulmonary aspiration, acute renal failure, alopecia (lixisenatide)
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; it also reduces sodium reabsorption, which may increase tubuloglomerular feedback, reduce intraglomerular pressure, and lower cardiac pre- and afterload.
SOLIQUA 100/33 combines insulin glargine, a basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with lixisenatide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jardiance
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Soliqua 100/33
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (11/12)
UnitedHealthcare
Jardiance
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Soliqua 100/33
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Jardiance
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Soliqua 100/33
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Jardiance Savings CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Soliqua 100/33.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JardianceView full Jardiance profile
Soliqua 100/33View full Soliqua 100/33 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.